Waters Corporation (WAT) News
Track canonical SquawkNews coverage tagged to WAT, Waters Corporation. This hub brings together deduplicated headlines about united states, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 18 indexed stories across 13 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Weekly Recap: Q2 BD COR high—throughput installs and Goldman Sachs $515 target
Waters Corporation (NYSE:WAT) is accelerating Q2 momentum with 15 BD COR high—throughput installs and plans to migrate more assays from BD MAX plus add an HPV home/self—test option, while Goldman Sachs reiterates a Buy a
NEWS | Sep 28, 2026, 11:06 AM UTC
H
WAT outlook supported by localization, pricing and integration momentum
TradingView reports strong Q2 results led by growth across instruments, recurring revenue and chemistry. China and pharma segments outperformed, while localization, pricing improvements and integration synergies support
EARNINGS | Sep 09, 2026, 03:55 PM UTC
H
WAT flags broad growth and China momentum after strong Q2
WAT says Q2 strength reflected broad-based growth across instruments, chemistry and diagnostics, with China and acquired businesses outperforming expectations. It cites integration synergies ahead of plan and expects sus
EARNINGS | Sep 09, 2026, 03:19 PM UTC
L
UBS raises Waters Corp price target to $490 from $375
UBS raised its price target on Waters Corp to $490.00 per share from $375.00, according to ratings actions cited by Benzinga.
EQUITY | Sep 09, 2026, 01:44 PM UTC
M
WAT statutory NPAT up 59%; EBIT margins expand
WAT reported statutory NPAT rose 59% and EBIT margins expanded, citing international growth and operational efficiencies.
EQUITY | Aug 31, 2026, 10:53 PM UTC
L
Waters price target raised to $480 by Piper Sandler
Waters Corp price target raised to $480.00 per share from $400.00 by Piper Sandler.
EQUITY | Aug 27, 2026, 04:52 PM UTC
L
Waters to present at Wells Fargo Healthcare conference
Waters Corporation said it will present at the Wells Fargo Healthcare Conference.
EQUITY | Aug 26, 2026, 01:01 PM UTC
H
Analysts Upgrade ADM, AEIS, CPNG, ENTG, KTOS, PLD, RA, VGNT, WAT
Multiple stocks upgraded by analysts
EQUITY | Aug 05, 2026, 10:59 AM UTC
H
Waters Q2 Sales $828M, Misses Estimate
Waters reports Q2 sales of $828M, below estimate
EARNINGS | Aug 04, 2026, 10:22 AM UTC
H
WAT Reports Q2 EPS 3.05
WAT beats Q2 EPS estimates
EARNINGS | Aug 04, 2026, 10:04 AM UTC
H
Waters Raises FY2026 Adj EPS Guidance from $14.40-$14.60 to $14.45-$14.65 vs $14.51 Est; Raises FY2026 Sales Guidance from $6.405B-$6.455B t
Waters (NYSE: WAT ) raises FY2026 Adj EPS guidance from $14.40-$14.60 to $14.45-$14.65 vs $14.51 analyst estimate. Raises FY2026 sales outlook from $6.405 billion-$6.455 billion to $6.415 billion-$6.476 billion vs $6.436
EARNINGS | Aug 04, 2026, 10:03 AM UTC
H
WAT - Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results
WAT - Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 04, 2026, 10:01 AM UTC
L
WAT - Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer - Click For Re
WAT - Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer
EQUITY | Jul 27, 2026, 12:11 PM UTC
L
TMO DHR WAT A in Tools and GH CAI in Diagnostics remain Buy rated in Q2 preview @ GSCO
TMO DHR WAT A in Tools and GH CAI in Diagnostics remain Buy rated in Q2 preview @ GSCO
EQUITY | Jul 15, 2026, 12:17 PM UTC
H
Waters price target raised to $390 from $350 at Morgan Stanley
Morgan Stanley analyst Kallum Titchmarsh raised the firm's price target on Waters to $390 from $350 and keeps an Equal Weight rating on the shares. The firm is updating its model ahead of the earnings report.
EQUITY | Jul 09, 2026, 11:00 AM UTC
L
Evercore ISI Adjusts Price Target on Waters to $410 From $380
() -- Waters (WAT) has an average rating of overweight and mean price target of $406.52, according to analysts polled by FactSet. ( covers equity, commodity and economic research from major banks and research firms in No
EQUITY | Jul 06, 2026, 01:06 PM UTC
M
WAT: Bernstein Reinstates Outperform
Bernstein analyst Eve Burstein reinstates Waters with an Outperform rating and $435 price target.
EQUITY | Jun 26, 2026, 01:14 PM UTC
L
WAT - IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precis
WAT - IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine
EQUITY | Jun 24, 2026, 12:02 PM UTC